HER2 Is Not a Predictive Biomarker of Benefit From Up-front Chemotherapy Plus Bevacizumab or Anti-EGFR, but Negative Prognostic Factor in pMMR/MSS RAS/BRAF Wild-Type mCRC By Ogkologos - September 29, 2025 416 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a large analysis of HER2 status in patients enrolled in 8 randomised clinical trials Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR New on NCI’s Websites for November 2021 November 5, 2021 Young Mom Battles Breast Cancer After Being Misdiagnosed with a Blocked... July 30, 2019 Do Black Lives Matter Less Than Those of Cancer Survivors? June 18, 2020 Final DFS Analysis Demonstrates that Adjuvant Osimertinib Improves DFS in Patients... February 13, 2023 Load more HOT NEWS FDA Approves Trastuzumab Deruxtecan for Any HER2-Positive Solid Cancer Age and Frailty Should Be Considered Independently When Evaluating Potential Risk... Bus Driver Wears Different Costume Each Day To Make Kids Smile... Outcome of EMA Assessment on Use of Lutetium (177Lu) in Treatment...
